ACETO Subsidiary, Rising Pharmaceuticals, Launches Generic Version of Nasalide(R)

Tue Jun 4, 2013 9:29am EDT

* Reuters is not responsible for the content in this press release.

PORT WASHINGTON, N.Y., June 4, 2013 (GLOBE NEWSWIRE) -- ACETO Corporation (Nasdaq:ACET), a global leader in the marketing, sale and distribution of products for Human Health, Pharmaceutical Ingredients and Performance Chemicals, today announced that Rising Pharmaceuticals Inc., its finished dosage form generics subsidiary, launched the 0.025% strength of Flunisolide Nasal Solution USP, an FDA approved generic version of Nasalide®. According to IMS Health data, U.S. market sales for Flunisolide, an anti-inflammatory steroid used to treat seasonal and perennial allergies, were approximately $37.3 million for the twelve months ended December 31, 2012. This is the eighth generic product launched by Rising Pharmaceuticals in fiscal 2013.

ABOUT ACETO

ACETO Corporation, incorporated in 1947, is a global leader in the marketing, sale and distribution of products for Human Health (finished dosage form generics and nutraceutical products), Pharmaceutical Ingredients (pharmaceutical intermediates and active pharmaceutical ingredients) and Performance Chemicals (specialty chemicals and agricultural protection products). With business operations in nine countries, ACETO and its Rising Pharmaceuticals subsidiary sells over 1,200 products used as RX generic drugs or raw materials in the pharmaceutical, nutraceutical, agricultural, coatings and industrial chemical industries. ACETO's global operations, including a staff of 25 in China and 12 in India, are distinctive in the industry and enable its worldwide sourcing and regulatory capabilities.

This news release contains forward-looking statements as that term is defined in the federal securities laws. To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward-looking and as such, are subject to known and unknown risks, uncertainties and contingencies, many of which are beyond the control of the Company, which could cause actual results and outcomes to differ materially from those expressed herein. Factors that could cause actual results to differ materially from those set forth or implied by any forward-looking statement include, but are not limited to, risks and uncertainties discussed in ACETO's reports filed with the Securities and Exchange Commission, including, but not limited to, ACETO's Annual Report or Form 10-K for the fiscal year ended June 30, 2012 and other filings. Copies of these filings are available at www.sec.gov. ACETO undertakes no obligation to publicly update or revise any forward-looking statements, whether from new information, future events or otherwise.

CONTACT: Investor Relations Contact:
         Stephanie Carrington
         The Ruth Group
         (646) 536-7023
         scarrington@theruthgroup.com
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.